The DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.
Cannabidiol for the treatment of psychosis in Parkinson's disease
Abstract
The management of psychosis in Parkinson's disease (PD) has been considered a great challenge for clinicians and there is a need for new pharmacological intervention. Previously an antipsychotic and neuroprotective effect of Cannabidiol (CBD) has been suggested. Therefore, the aim of the present study was to directly evaluate for the first time, the efficacy, tolerability and safety of CBD on PD patients with psychotic symptoms. This was an open-label pilot study. Six consecutive outpatients (four men and two women) with the diagnosis of PD and who had psychosis for at least 3 months were selected for the study. All patients received CBD in flexible dose (started with an oral dose of 150 mg/day) for 4 weeks, in addition to their usual therapy. The psychotic symptoms evaluated by the Brief Psychiatric Rating Scale and the Parkinson Psychosis Questionnaire showed a significant decrease under CBD treatment. CBD did not worsen the motor function and decreased the total scores of the Unified Parkinson's Disease Rating Scale. No adverse effect was observed during the treatment. These preliminary data suggest that CBD may be effective, safe and well tolerated for the treatment of the psychosis in PD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In an open clinical trial with six PD outpatients, we found a significant reduction in the BPRS and the Parkinson Psychosis Questionnaire (PPQ) scores with CBD (150–600 mg/day) added to the usual treatment.”
From Translational investigation of the therapeutic potential of Cannabidiol (CBD): Toward a new age (2018) · cites this paper as [73]
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
The FAB: A frontal assessment battery at bedside
Dubois, B., Slachevsky, A., Litvan, I., & Pillon, B. (2000) · Neurology · doi:10.1212/wnl.55.11.1621 · Cited by 3,913
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481
The orphan receptor GPR55 is a novel cannabinoid receptor
Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, N., Leonova, J., Elebring, T., Nilsson, K., Drmota, T., & Greasley, P. J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707460 · Cited by 1,568
Hallucinations in Parkinson's disease: Prevalence, phenomenology and risk factors
Fénelon, G. (2000) · Brain · doi:10.1093/brain/123.4.733 · Cited by 1,035
Felder, C., Joyce, K. E., Briley, E. M., Mansouri, J., Mackie, K., Blond, O., Lai, Y., Ma, A. L., & Mitchell, R. (1995) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10492-6 · Cited by 900
Thomas, A., Baillie, G. L., Phillips, A. M., Razdan, R. K., Ross, R. A., & Pertwee, R. G. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707133 · Cited by 763
Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH work group
Ravina, B., Marder, K., Fernandez, H. H., Friedman, J. H., McDonald, W., Murphy, D., Aarsland, D., Babcock, D., Cummings, J., Endicott, J., et al. (2007) · Movement Disorders · doi:10.1002/mds.21382 · Cited by 528
Bech, P., Kastrup, M., & Rafaelsen, O. J. (1986) · PubMed · Cited by 467
Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug
Zuardi, A. W., Crippa, J. A. S., Hallak, J. E. C., Moreira, F. A., & Guimarães, F. S. (2006) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2006000400001 · Cited by 415
Self-citation
Research works printed but not linked: 7
- Bech, P., 1986, Acta Psychiatr Scand Suppl, 326, 1
- 10.1111/j.1460-9568.1998.00292.x · DOI
- Fahn, S., Elton, RL Members of the UPDRS Development Committee ( 1987) Unified Parkinson’s Disease Rating Scale (UPDRS) . In: Fahn, S, Marsden, CD, Calne, DB , Goldstein, M (eds), Recent Developments in Parkinson’s Disease, Vol. 2. Florahm Park, NJ: Macmillan Health Care Information , pp. 153-164.
- First, MB, 1997, Structured Clinical Interview for DSM-IV Axis I Disorders - Clinician Version (SCID-CV)
- National Institute of Mental Health (1976) CGI - Clinical Global Impression. In: Guy, W (ed), ECDEU Assessment Manual of Psychopharmacology (revised) . Rockville, MD: NIMH, pp. 534- 537.
- Zuardi, AW, 1994, Rev ABPAPAL, 16, 63
- Zuardi, AW, 1995, J Clin Psychiatry, 56, 485
Cited by
Sorted by citations
Items 301–354 of 354
Cannabis bij psychotische stoornissen
Neven, A. K. (2017) · Verslaving · doi:10.1007/s12501-017-0126-x
Cannabinoide in der Behandlung der Parkinson-Erkrankung
Gandor, F., & Ebersbach, G. (2017) · Aktuelle Neurologie · doi:10.1055/s-0043-115380
Screening of a Histone Methyltransferase Inhibitor in Animal Models of Psychiatric Illness
Kosowan, J. (2014) · TSpace (University of Toronto)
Exploring Novel Treatment Approaches for Post-Traumatic Stress Disorder
Murkar, A. (2020) · uO Research (University of Ottawa) · doi:10.20381/ruor-24279
Cannabidiol – decades of research and current clinical uses
Rădoi, V., & Cicu, G. (2019) · Psihiatru ro · doi:10.26416/psih.59.4.2019.2605
Role of the pharmacist in the care of patients using cannabis
El‐Alfy, A. T. (2020) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2020.04.002
Cannabinoids in Neurologic Conditions
Gaston, T. E., Szaflarski, J. P., Bowling, A. C., Liu, Y., Seawalt, T., Leehey, M. A., Nelson, E. L., Rajpal, S., Villavicencio, A. T., Bauer, A. M., et al. (2020) · Springer eBooks · doi:10.1007/978-3-030-45968-0_10
Mahmoud, M. M. (2015) · OpenCommons at University of Connecticut (University of Connecticut)
Zamarrenho, L. G. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2020.tde-23082020-104553
Síndrome metabólico y enfermedad de Parkinson
Gómez-Chavarı́n, M., & Morales-Gómez, M. D. R. (2020) · Archivos de Neurociencias · doi:10.31157/an.v25i2.236
Rossi, G. N. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2020.tde-08022021-150020
de Almeida, C. M. O. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2021.tde-05072021-154535
Psychosis and Parkinson’s Disease
Vaughan, C. L., & Goldman, J. G. (2021) · Current clinical neurology · doi:10.1007/978-3-030-75898-1_17
Current awareness in human psychopharmacology
(2010) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1062
Loewy, D. H., Poceta, J. S., & Dawson, A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822963-7.00342-x
Costa, K. C. M. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2023.tde-05062023-141905
Medical use of cannabidiol and impact on cancer cell viability
Raup‐Konsavage, W. M., & Vrana, K. E. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-90036-2.00027-2
Amaral, D. S. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2023.tde-08052023-105940
On the possible prospects for the use of cannabis for medical purposes
Titulova, A. P., & Гребнева, Н. Ю. (2023) · Russian Military Medical Academy Reports · doi:10.17816/rmmar340773
Effective Transdermal Patch with Cannabidiol-Loaded Nanoparticles and its Pharmacokinetics in VivoPreprint
Chu, P.-C., Liao, M.-H., Liu, M.-G., Li, C.-Z., & Lai, P. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4621884
Beyond conventional therapy: cannabinoids as an alternative in parkinson's disease
Alves, L. B., Carneiro, A. L. B., Bolzani, C. M. T., Procaci, V. R., Crippa, J. A. S., & Felicio, A. C. (2023) · OBSERVATÓRIO DE LA ECONOMÍA LATINOAMERICANA · doi:10.55905/oelv21n12-194
Self-citationЕФЕКТИ І ТЕРАПЕВТИЧНИЙ ПОТЕНЦІАЛ КАНАБІДІОЛУ У РАЗІ КАРДІОВАСКУЛЯРНИХ ЗАХВОРЮВАНЬ
Shevchuk, M. M. (2023) · Health & Education · doi:10.32782/health-2023.4.14
Panegyres, P. K., Lind, K. L., MacFarlane, C. A., & Gurney, A. L. (2024) · Neurodegenerative Disease Management · doi:10.2217/nmt-2023-0011
Cannabidiol Therapy for Comorbid Schizophrenia and Addiction: A Guide for Clinical PracticePreprint
Maj, J., & Francis, A. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4857098
Current options for cannabinoids in the treatment of Parkinson's disease
Zdziebło, P., Machała-Ćwikła, E., Łapińska, U., Ćwikła, P., Machała, K., Zdziebło, A., Machała, D., Zdziebło, K., & Bieniasz, A. (2024) · Quality in Sport · doi:10.12775/qs.2024.17.52922
The chemistry and pharmacology of tetrahydrocannabinol and cannabidiol
Jana, C. E., Mwambyale, T., Chirambo, G., Gwedela, M. N. V., Chimphepo, L., & Chikowe, I. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95927-8.00019-0
Neary, J. P., Singh, J., Alcorn, J., Laprairie, R. B., Dehghani, P., Mang, C. S., Björnson, B., Hadjistavropoulos, T., Bardutz, H. A., Bhagaloo, L., et al. (2024) · BMC Neurology · doi:10.1186/s12883-024-03847-1
Piloto, G. C., da Silva, J. C., Germann, K. C., & Czepula, A. I. D. S. (2024) · Research Society and Development · doi:10.33448/rsd-v13i12.47643
Indicações do Uso do Canabidiol em Neurologia
Rossi, G. B., Ferreira, J. R., Zwang, I. C., Dantas, V. A., Ferreira, S. H., GONÇALVES, G. B., Terra, V. M., & Walter, I. B. S. (2024) · Brazilian Journal of Implantology and Health Sciences · doi:10.36557/2674-8169.2024v6n12p2222-2234
Utilização de Canabidiol no tratamento de crianças com Transtorno do Espectro Autista
Amaral, M. I. P. D. C., Marins, F. R., & Filho, M. L. (2025) · Revista Científica Multidisciplinar Núcleo do Conhecimento · doi:10.32749/nucleodoconhecimento.com.br/psicologia/utilizacao-de-canabidiol
Perinatal cannabinoid exposure
Iezzi, D., & Manzoni, O. J. (2025) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-443-13908-6.00014-1
Role of the endocannabinoid system in schizophrenia: From preclinical to human evidence
Martino, S. D., Białoń, M., Drago, F., Starowicz, K., & Micale, V. (2025) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-443-13908-6.00030-x
Huang, X. (2011) · Research Online (University of Wollongong)
Boury‐Esnault, N., Marschal, C., Probst, J.-M. K., & Barnathan, G. (2002) · INFM-OAR (INFN Catania) · doi:10.5281/zenodo.155630
Orjuela-Rojas, J. M., García Orjuela, X., & Ocampo-Serna, S. (2021) · Figshare · doi:10.6084/m9.figshare.14913815
Miller, C. O. G. (2025) · Springer eBooks · doi:10.1007/978-3-032-13315-1_3
Pisani, S., Váša, F., Velayudhan, L., & Bhattacharyya, S. (2026) · Movement Disorders · doi:10.1002/mds.70222
Kitchigina, V. F., & Shubina, L. (2026) · Neuroscience · doi:10.1016/j.neuroscience.2026.03.023 · Cited by 1
Cilia, J., Guillermin, O., McCreary, A. C., Virley, D. J., & Li, J. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261456216
Ajalin, R., Al‐Abdulrasul, H., Tuisku, J., Karrasch, M., Hirvonen, J., Kirjavainen, A. K., Zetterberg, H., Rinne, J. O., & Brück, A. (2026) · Journal of Parkinson s Disease · doi:10.1177/1877718x261457830
Plant-derived therapies in Parkinson’s disease: a systematic review of clinical evidence
Sukmueng, N., Phokaewvarangkul, O., & Bhidayasiri, R. (2026) · Journal of Neural Transmission · doi:10.1007/s00702-026-03239-4
Lombardi, G., Shatalina, E., O’Neill, A., Wilson, R. P., Mehta, M. A., & Bhattacharyya, S. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261470456
Cannabis and Cannabinoids: The Medical Potential of Cannabidiol in Mental and Neurological Disorders
Solea, R., Șerban, E., Călugăr-Șolea, S.-F., Máthé, E., Blebea, N. M., Hancu, G., & Serban, G. (2026) · Pharmaceuticals · doi:10.3390/ph19081238 · Cited by 1
Kubota, G. T., Parmera, J. B., Deltreggia, M., Martins, P. N., Alves, A. L. D. M., de Falcone, A. C. M., Santana, A. R., Falcão, M. A. P., Dias, M. A., Moreira, L. I., et al. (2026) · Movement Disorders · doi:10.1002/mds.70449
Uršič, M., Karaer, M. C., Gregorič, A., Vake, T., & Snoj, T. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1931847
Cannabinoids and psychosis : cause and treatment
Morrison, P. D. (2012) · UPT. Syiah Kuala University Library (Syiah Kuala University)
Metadata
- Authors
- Zuardi, A., Crippa, J., Hallak, J., Pinto, J., Chagas, M., Rodrigues, G., Dursun, S., & Tumas, V.
- Affiliations
- Universidade de São Paulo (BR)
- Department of Neuropsychiatry and Medical Psychology, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil
- Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada
- Corresponding author
- Zuardi, AW
- ORCID
- Tumas, V.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2008-09-18
- Volume
- 23
- Issue
- 8
- Pages
- 979-983
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W1967281437
- Cited by
- 355
- References
- 30
- Citations by year
- 2026: 14 · 2025: 15 · 2024: 28 · 2023: 34 · 2022: 28 · 2021: 33 · 2020: 39 · 2019: 29 · 2018: 21 · 2017: 20 · 2016: 17 · 2015: 12 · 2014: 14 · 2013: 8 · 2012: 9
- FWCI
- 7.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Scientific Electronic Library Online (São Paulo Research Foundation, Latin American and Caribbean Center on Health Sciences Information, Conselho Nacional de Desenvolvimento Científico e Tecnológico) (publishedVersion)
- Funders
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- National Institutes of Health
- National Institute of Mental Health
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- cannabidiol, Parkinson's disease, psychosis, antipsychotic drugs, neuroprotection, motor function, drug safety and tolerability, Brief Psychiatric Rating Scale
- MeSH terms
- Adult, Aged, Cannabidiol, Female, Humans, Male, Middle Aged, Parkinson Disease, Pilot Projects, Psychotic Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review